Session Information
Date: Monday, September 23, 2019
Session Title: Restless Leg Syndrome, RBD and Other Sleep Disorders
Session Time: 1:45pm-3:15pm
Location: Les Muses Terrace, Level 3
Objective: To compare the Sleep Profiler (SP), an FDA-approved device for home evaluation of sleep disorders, to the gold standard sleep laboratory polysomnogram (PSG) in evaluation of dream enactment behavior.
Background: Diagnosis of REM sleep behavior disorder (RBD) is strongly associated with risk of synucleinopathy, particularly Lewy body dementia and Parkinson disease, but requires PSG for confirmatory diagnosis. Capturing RBD during a one-night PSG opportunity can be challenging due to night-to night variability of dream enactment behaviors and can be costly to repeat.
Method: During an overnight PSG (with seizure and four-limb RBD protocol), we simultaneously collected Sleep Profiler data on 6 subjects recruited with recurrent dream enactment behavior but no evidence of neurodegenerative disease. Independent sleep reviewers analyzed the data from each source.
Results: Sleep efficiencies by PSG and SP were 85.3% and 84.6%, respectively, while the median sleep times were identical (358 min). The median sleep onset latency for the PSG was 16 min and 22 min for the SP with a median difference of 5 minutes. The PSG and SP REM percentages were 14.5% and 13%, with a median difference of 1.3%. The SP appeared to under-report N3 sleep and over-report N1 sleep. Of the 6 subjects, four had REM sleep without atonia (RSWA) and concordant dream enactment on both the PSG data and the SP data, but comparisons were not completely blinded. Of the 4 subjects with RSWA, 3 had newly diagnosed obstructive sleep apnea (mean AHI 13.3, range 9.7-16.2/hr).
Conclusion: The Sleep Profiler is worthy of larger scale validation studies to show equivalence with PSG in diagnosis of RBD. We suggest the SP be configured to include capabilities to measure airflow signals to screen for sleep apnea and monitor movement in all four limbs for better detection of RSWA. Such studies should also measure potential benefits in terms of cost and feasibility of recruitment of RBD subjects into neurodegenerative disease research trials.
To cite this abstract in AMA style:
D. Shprecher, D. Levendowski, C. Guevarra, J. Lee-Iannotti, G. Lazarz. Pilot Study Comparing Home Sleep Profiler to In-laboratory Polysomnogram for REM Sleep Behavior Disorder Diagnosis [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/pilot-study-comparing-home-sleep-profiler-to-in-laboratory-polysomnogram-for-rem-sleep-behavior-disorder-diagnosis/. Accessed June 14, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/pilot-study-comparing-home-sleep-profiler-to-in-laboratory-polysomnogram-for-rem-sleep-behavior-disorder-diagnosis/